İbrahim Tekeoğlu1, Gönül Gürol2, Halil Harman1, Engin Karakeçe3, İhsan Hakkı Çiftçi4. 1. Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Faculty of Medicine, Sakarya University, Sakarya, Turkey. 2. Department of Medical Physiology, Faculty of Medicine, Sakarya University, Sakarya, Turkey. 3. Department of Microbiology, Sakarya University Education and Research Hospital, Sakarya, Turkey. 4. Department of Microbiology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.
Abstract
AIM: The aim of this study was to investigate the relationship between hematological markers and disease activity in patients with rheumatoid arthritis (RA). METHOD: The study was designed and performed in the Department of Rheumatology of the Sakarya University Faculty of Medicine. In total, 102 patients with RA were retrospectively enrolled. We used the Disease Activity Score of 28 joints (DAS28) instrument to evaluate disease activity. Laboratory assessments included complete blood cell counts, measurement of erythrocyte sedimentation rate (ESR) and assessment of C-reactive protein (CRP) level. Exclusion criteria included active infection and/or the presence of any hematological, cardiovascular or metabolic disorder. RESULTS: We found that the neutrophil lymphocyte ratio (NLR) and mean platelet volume (MPV) varied by disease activity status. NLR values correlated positively with the DAS28 scores of RA patients. Especially, higher NLR values (3.92 ± 0.31) were evident in the group exhibiting high-level disease activity, whereas the MPV values were lowest (7.11 ± 0.91 fL) in this group. Additionally, no significant difference was evident between DAS28 scores and platelet distribution width (PDW) values in patients with RA (r = -0.055, P = 0.124). CONCLUSIONS: We found that the MPV value may serve as a marker of the absence of acute-phase disease, and the NLR level as a marker of the presence of such disease, in patients with RA. More detailed analysis of disease activity is required to further explain the associations of the markers described above with disease activity.
AIM: The aim of this study was to investigate the relationship between hematological markers and disease activity in patients with rheumatoid arthritis (RA). METHOD: The study was designed and performed in the Department of Rheumatology of the Sakarya University Faculty of Medicine. In total, 102 patients with RA were retrospectively enrolled. We used the Disease Activity Score of 28 joints (DAS28) instrument to evaluate disease activity. Laboratory assessments included complete blood cell counts, measurement of erythrocyte sedimentation rate (ESR) and assessment of C-reactive protein (CRP) level. Exclusion criteria included active infection and/or the presence of any hematological, cardiovascular or metabolic disorder. RESULTS: We found that the neutrophil lymphocyte ratio (NLR) and mean platelet volume (MPV) varied by disease activity status. NLR values correlated positively with the DAS28 scores of RApatients. Especially, higher NLR values (3.92 ± 0.31) were evident in the group exhibiting high-level disease activity, whereas the MPV values were lowest (7.11 ± 0.91 fL) in this group. Additionally, no significant difference was evident between DAS28 scores and platelet distribution width (PDW) values in patients with RA (r = -0.055, P = 0.124). CONCLUSIONS: We found that the MPV value may serve as a marker of the absence of acute-phase disease, and the NLR level as a marker of the presence of such disease, in patients with RA. More detailed analysis of disease activity is required to further explain the associations of the markers described above with disease activity.
Authors: O Zengin; M E Onder; A Kalem; M Bilici; I H Türkbeyler; Z A Ozturk; B Kisacik; A M Onat Journal: Z Rheumatol Date: 2018-03 Impact factor: 1.372
Authors: Deonilson Schmoeller; Maria Mercedes Picarelli; Terezinha Paz Munhoz; Carlos Eduardo Poli de Figueiredo; Henrique Luiz Staub Journal: Front Med (Lausanne) Date: 2017-09-06
Authors: Mustafa Serdar Sağ; Sinem Sağ; İbrahim Tekeoğlu; Ayhan Kamanli; Kemal Nas; Halil Harman Journal: Arch Rheumatol Date: 2017-09-13 Impact factor: 1.472